HCA Healthcare, Inc. · HCA · FY2024 Q4 · Calendar Q1 2025

HCA: Solid growth, with payment and weather risks still in focus

HCA's current evidence supports a constructive operating thesis: service demand, network expansion, cash generation, and efficiency initiatives provide several growth levers. The case is less secure if supplemental payments weaken, weather costs recur, payer mix deteriorates, or policy changes pressure outpatient economics.

Reported Before market openNYSEHealthcare $99.34B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $6.06
EPS surprise — Reported versus consensus
Reported revenue — Consensus $18.23B
Revenue surprise — Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -3.8% Event window
SPY move -0.3% Same window
Abnormal move -3.5% Stock minus SPY
Volume 2.2× Versus trailing sessions
Subsequent drift +2.1% Up to 20 sessions
HCASPY benchmark

Ask FN2 about HCA FY2024 Q4

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

The latest analysis shows continued growth despite hurricane-related costs, a stable capital outlook, and a broader set of operational initiatives. Compared with the prior quarter, the emphasis shifted from managing the immediate hurricane impact to funding network expansion, technology, workforce development, and shareholder returns while retaining attention on Medicaid variability and regulatory risk.

Guidance delta

Management maintained its outlook while incorporating hurricane-related effects into the 2025 framework.

Key takeaways

  • Management described roughly 6% fourth-quarter revenue growth and 5.4% adjusted EPS growth despite hurricane-related costs.
  • Full-year cash generation supports planned capital investment, network expansion, and shareholder returns.
  • Operational priorities include ER and OR optimization, case management, AI deployment, and workforce development.
  • The main offsets are hurricane exposure, variable Medicaid supplemental payments, payer-mix changes, and possible policy pressure.

Management priorities

  • Deploy $5–$5.2 billion of capital toward network development, new ER beds, and operating-room optimization.
  • Expand the outpatient surgery-center network and pursue the Manchester, New Hampshire hospital acquisition.
  • Advance AI across clinical, operational, and administrative processes.
  • Continue labor-development programs, including the Galen College of Nursing partnership.

Follow HCA with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
HCA REVENUE earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q1 '24 estimate $17B Q1 '24 actual $17B, beat Q2 '24 estimate $17B Q2 '24 actual $17B, beat Q3 '24 estimate $18B Q3 '24 actual $17B, miss Q2 '25 estimate $18B Q2 '25 actual $19B, beat Q3 '25 estimate $19B Q3 '25 actual $19B, beat Q4 '25 estimate $20B Q4 '25 actual $20B, miss Q1 '26 estimate $19B Q1 '26 actual $19B, beat Q2 '26 estimate $20B Q2 '26 actual $20B, beat Q3 '26 estimate $19B Q4 '26 estimate $20B Q1 '27 estimate $20B Q2 '27 estimate $21B
Show 1 more >

Analyst Consensus ?

ConsensusBuy45 ratings
Bullish2862.2%
Neutral1533.3%
Bearish24.5%

Analyst 52W Price Targets

$458.84Previous close
$224Low
$400.65Average
$579High

Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 19, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
TD Cowen Buy BuyMaintainOct 12, 2026
RBC Capital Outperform OutperformMaintainOct 7, 2026
Leerink Partners Outperform OutperformMaintainSep 18, 2026
JP Morgan Neutral NeutralMaintainAug 20, 2026
Wells Fargo Equal Weight Equal WeightMaintainAug 3, 2026
Show 40 more rating actions

Named analyst price targets

Upside is calculated against the persisted previous close $458.84. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
RBC CapitalAnalyst unavailable$496$438.46 +8.1%Oct 7, 2026
BMO CapitalAnalyst unavailable$495$438.12 +7.9%Sep 22, 2026
Goldman SachsAnalyst unavailable$485$389.62 +5.7%Jul 28, 2026
UBSAnalyst unavailable$579$390.7 +26.2%Jul 27, 2026
Deutsche BankAnalyst unavailable$476$387.41 +3.7%Jul 27, 2026
See 116 more

Track every rating change on HCA the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services. These hospitals additionally offer a broad range of outpatient care, such as ambulatory surgery, laboratory testing, radiology, respiratory therapy, cardiology, and physical therapy. Beyond its hospital infrastructure, HCA Healthcare operates numerous specialized outpatient facilities.…

Historical context

All HCA earnings

Latest beats and misses

Who reports next

Get the HCA recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2025-01-10T00:01:05.473193+00:00
  3. Polygon adjusted daily market bars · 2026-10-19T09:50:44.776679+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-19T09:50:44.773959+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-19. For educational purposes only; not investment advice.